Egalet (EGLT) Tops Q2 EPS by 6c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. FIS
3. ARM
4. BROS
5. QCOM
6. EXPE
7. PAYC
8. APP
9. FSLY
10. CPAY

Go back to Egalet (EGLT) Tops Q2 EPS by 6c, Revenues Miss

Egalet Reports Second Quarter 2018 Financial Results

August 8, 2018 6:02 AM EDT

WAYNE, Pa., Aug. 8, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today reported financial results for the second quarter ended June 30, 2018 and provided updates on its commercial products: SPRIX® (ketorolac tromethamine) Nasal Spray, OXAYDO® (oxycodone HCI, USP) tablets for oral use only CII and ARYMO® ER (morphine sulfate) extended-release tablets for oral use CII.    

... More